Omeros (OMER) Set to Release Quarterly Earnings on Monday

Omeros Corporation, traded on NASDAQ under the symbol OMER, is expected to announce its quarterly earnings data prior to the market opening on Monday, April 7th. Analysts are forecasting that the company will report earnings of ($0.71) per share for this quarter.

Current Stock Performance

On the stock market, OMER opened at $8.47 on Monday. The 50-day moving average for the stock stands at $8.69, while the 200-day moving average is at $7.55. Over the past year, Omeros has experienced a low of $2.61 and a high of $13.60. The company holds a market capitalization of approximately $490.84 million, with a price-to-earnings (P/E) ratio of -3.67 and a beta value of 2.03, indicating greater volatility compared to the market.

Analyst Insights

In recent weeks, several analysts have provided updates on Omeros shares. Needham & Company LLC maintained a “hold” rating on the stock in a report from January 17th. StockNews.com downgraded the rating from “hold” to “sell” on March 21st. Conversely, D. Boral Capital reiterated a “buy” rating and set an ambitious price target of $36.00 for Omeros shares also on March 21st. Currently, the stock has received mixed ratings, with one analyst issuing a sell rating, two assigning a hold rating, two giving a buy rating, and one granting a strong buy rating. Data from MarketBeat indicates that Omeros has a consensus rating of “Moderate Buy” with a price target averaging $22.50.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of small-molecule and protein therapeutics. Its focus lies in orphan indications and conditions that affect the immune system, including complement-mediated diseases, cancers, and disorders related to addiction and compulsion. Omeros's pipeline includes Narsoplimab (OMS721/MASP-2), which has already completed a pivotal trial for treating thrombotic microangiopathy associated with hematopoietic stem-cell transplants (TA-TMA). It is currently undergoing a Phase III trial aimed at treating immunoglobulin A nephropathy (IgAN) and a Phase II trial for COVID-19 treatment.

Additional Resources

• Learn about five stocks we like better than Omeros
• Understanding asset allocation: A key for successful portfolios
• Venezuelan tariffs and their impact on investment opportunities
• Important information on over-the-counter (OTC) stocks
• MarketBeat Weekly Overview
• Information on the Dow Jones Industrial Average (DJIA)
• Should you consider buying into UPS stock at this time?

Omeros, Earnings, Stock